![Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial) - ScienceDirect Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0190962220326256-gr1.jpg)
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial) - ScienceDirect
![INDIVIDUAL ARTICLE: Vehicles Matter: Calcipotriene and Betamethasone Dipropionate Foam as a Topical Psoriasis Therapy - JDDonline - Journal of Drugs in Dermatology INDIVIDUAL ARTICLE: Vehicles Matter: Calcipotriene and Betamethasone Dipropionate Foam as a Topical Psoriasis Therapy - JDDonline - Journal of Drugs in Dermatology](https://s3.amazonaws.com/dl.jddonline.com/articleimages/22_9_M7714_SF376528_Leo+Pharma+Enstilar_SUPPL2/Real-World-Evidence-on-the-Use-of-Calcipotriene-and---Betamethasone-Dipropionate-Aerosol-Foam-0.005%25-0.064%25-in--the-Treatment-of-Psoriasis--A-Review-of-Investigator-Initiated---Studies-Around-the-Globe_Figure1.png)
INDIVIDUAL ARTICLE: Vehicles Matter: Calcipotriene and Betamethasone Dipropionate Foam as a Topical Psoriasis Therapy - JDDonline - Journal of Drugs in Dermatology
![PDF] Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis | Semantic Scholar PDF] Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/22a7905676f40cb98a07534fa8ebb696a2b0c58b/4-Figure3-1.png)
PDF] Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis | Semantic Scholar
![These highlights do not include all the information needed to use SORILUX safely and effectively. See full prescribing information for SORILUX. SORILUX (calcipotriene) foam, for topical use Initial U.S. Approval: 1993 These highlights do not include all the information needed to use SORILUX safely and effectively. See full prescribing information for SORILUX. SORILUX (calcipotriene) foam, for topical use Initial U.S. Approval: 1993](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=sorilux-09.jpg&id=675818)
These highlights do not include all the information needed to use SORILUX safely and effectively. See full prescribing information for SORILUX. SORILUX (calcipotriene) foam, for topical use Initial U.S. Approval: 1993
![JCM | Free Full-Text | Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment JCM | Free Full-Text | Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment](https://www.mdpi.com/jcm/jcm-10-05589/article_deploy/html/images/jcm-10-05589-g001.png)
JCM | Free Full-Text | Efficacy and Safety of Different Formulations of Calcipotriol/Betamethasone Dipropionate in Psoriasis: Gel, Foam, and Ointment
![The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes - JDDonline - Journal of Drugs in Dermatology The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes - JDDonline - Journal of Drugs in Dermatology](https://s3.amazonaws.com/dl.jddonline.com/articleimages/article_3621/Figure-1.jpg)